Welcome to our dedicated page for Kairos Pharma, LTD. SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. (KAPA) announced that on September 14, 2026 it issued a new investor presentation that will be posted on its website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026. Chief Executive Officer John Yu will use this presentation to provide an update on the company’s clinical program and activities. The investor presentation is furnished as Exhibit 99.1 and is not deemed filed or incorporated by reference for Securities Act or Exchange Act purposes.
Kairos Pharma, Ltd. (KAPA) approved and implemented a 1-for-7 reverse stock split of its common stock. Stockholders had previously authorized the board to implement a reverse split in a range between 1-for-3 and 1-for-250, and the board selected a 1-for-7 ratio.
The reverse split becomes effective September 1, 2026, at the start of trading, when KAPA will trade on the NYSE American on a split-adjusted basis with new CUSIP 48301N203. Every seven shares outstanding will be reclassified into one share, with no change to the $0.001 par value or to the number of authorized common or preferred shares. Fractional positions will be rounded up to the nearest whole share. Conversion rates and exercise prices for outstanding convertible notes, warrants and equity awards will be adjusted proportionately. Kairos states the reverse split is intended to reduce the number of outstanding shares, increase the per-share trading price, and help maintain compliance with NYSE American listing requirements.
Kairos Pharma, Ltd. reported no revenue and a net loss of $3,042 thousand for the six months ended June 30, 2026, compared with a loss of $2,684 thousand a year earlier, reflecting higher research and development spending of $1,303 thousand and general and administrative expenses of $1,804 thousand.
Cash and cash equivalents were $2,626 thousand and total assets $4,456 thousand, while operating cash outflows were $2,048 thousand in the first half of 2026. The company raised $392 thousand in gross proceeds via an at-the-market offering during the period and another $911 thousand afterward. Management and the auditor state that recurring losses, cash burn, and limited cash raise substantial doubt about Kairos’ ability to continue as a going concern. Disclosure controls and procedures were also concluded to be not effective. Kairos remains a clinical-stage oncology biotech with multiple license and manufacturing commitments and no approved products.
Kairos Pharma, Ltd. entered into an Agreement for the Support of Investigator / Institution Initiated Research with Bayer HealthCare Pharmaceuticals Inc. on July 16, 2026. Bayer will provide radium-223 (XOFIGO) for a study evaluating XOFIGO in combination with Kairos’ antibody ENV-105 (carotuximab) in models of prostate cancer bone metastasis.
Kairos is responsible for initiating, managing and financing the study, must obtain Bayer’s prior written approval before making material protocol changes, and will deliver final analysis, interpretation and conclusions to Bayer within 6 months after study completion. A related press release highlights ENV-105 Phase 2 data in resistant metastatic castration-resistant prostate cancer, including an 86% clinical benefit rate and median progression-free survival of more than 13 months, and describes the ENV-105 plus XOFIGO combination as targeting a $570M–$1.3B addressable global market.
Kairos Pharma, Ltd. is reporting interim safety data from an ongoing Phase 1 trial of ENV-105 (carotuximab) combined with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer. Among 13 treated patients, no serious adverse events (Grade 3 or higher) have been observed that are attributed to ENV-105, and all side effects have been manageable with standard supportive care. The study is designed to assess safety, tolerability, and a recommended Phase 2 dose.
ENV-105 is a CD105-targeting antibody intended to overcome resistance to osimertinib, the current gold-standard first-line therapy in EGFR-mutated NSCLC. The company highlights the EGFR-NSCLC market at about $10 billion, growing at a 10.5% CAGR and projected to exceed $13 billion by 2030. ENV-105 is also being evaluated in castrate-resistant prostate cancer, where a Phase 2 trial has shown median progression-free survival exceeding 13 months compared with standard care. The company includes forward-looking statements about the potential of ENV-105 across multiple tumor types.
Kairos Pharma Ltd. reported the results of its 2026 annual stockholder meeting, where 13,450,506 of 21,411,198 eligible common shares were voted, representing 62.81% participation. All four director nominees were elected for one-year terms. Stockholders ratified Weinberg & Company, P.A. as auditor for the year ending December 31, 2026. They also approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1:3 and 1:250, to be implemented at the Board’s discretion. On an advisory basis, stockholders approved executive compensation. In addition, they approved adding 5,000,000 shares to the 2023 Equity Incentive Plan and an evergreen feature allowing a 5% annual share increase for ten years.
Kairos Pharma Ltd. provides a mid-year 2026 update highlighting pipeline expansion and upcoming milestones. The company signed a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for EGFR-mutated lung cancer, part of a treatment landscape valued at $16.2B in 2026. Kairos plans to start a Phase 1 study of CL-741 in EGFR-mutated lung cancer and continue Phase 1 and Phase 2 trials of its lead antibody ENV-105 in non-small cell lung and castrate-resistant prostate cancer. The company notes it is a lean operation with a low monthly burn rate and has secured more than $8 million in non-dilutive funding to support its preclinical and clinical assets.
Kairos Pharma, Ltd. is asking stockholders at its June 29, 2026 virtual annual meeting to elect four directors, ratify Weinberg & Company, P.A. as auditor, and approve several governance items. Proposals include authority for a reverse stock split at a ratio between 1:3 and 1:250 and an advisory vote on executive pay.
The company also seeks approval to add 5,000,000 shares to its 2023 Equity Incentive Plan and adopt an evergreen provision for an automatic 5% annual share increase for ten years. Stockholders of record on May 15, 2026, when 21,411,198 common shares were outstanding, may vote online, by phone, mail, or during the live webcast.
Kairos Pharma, Ltd. furnished an investor presentation in connection with its appearance at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation, available on the company’s website, is intended to update investors on its clinical program and partnering activities.
The materials are furnished, not filed, under Item 8.01 of the Exchange Act and attached as Exhibit 99.1, meaning they are not subject to Section 18 liability or automatically incorporated into other securities law filings.